Consecuencias metabólicas y funcionales del envejecimiento en la salud y la enfermedad
Considerable heterogeneity in the aging population has been observed. The exceptional longevity of individuals reaching 100 years old, so-called centenarians may be an example of life-long healthy aging, or added years may be spent in poor health with decreased physical and cognitive functioning. Current knowledge of the aging experience and the trajectories of physical and cognitive decline across various age groups are not well-understood, yet crucial to prevent spending added years in disease. Hence, the study objective is to develop the metabolic profile associated with aging-related disorders measured as the incidence of impaired functional capacity, cognitive function, and/or well-being.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Our lab developed a pulse method combining multiple stable tracers to study multiple metabolic pathways in the same individual simultaneously. By measuring whole-body metabolism in a large group of older adults, we may be able to unravel age-related deterioration in protein turnover (synthesis and breakdown) that contributes to impaired functional capacity. Metabolic profiles could explain differences in pathways in the aging process with a special interest in the metabolism of amino acids as they have been associated with aging-related disorders. Studies on the effect of aging on metabolism might serve as potential therapeutic targets.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Laura Ruebush, PhD
- Número de teléfono: 979-422-1789
- Correo electrónico: le.ruebush@ctral.org
Copia de seguridad de contactos de estudio
- Nombre: Marielle Engelen, PhD
- Número de teléfono: 979-422-1789
- Correo electrónico: mpkj.engelen@ctral.org
Ubicaciones de estudio
-
-
Texas
-
College Station, Texas, Estados Unidos, 77845
- Reclutamiento
- Human Clinical Research Building
-
Contacto:
- Laura Ruebush, PhD
- Correo electrónico: le.ruebush@ctral.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
We will screen 400 subjects (to complete n=320). This number includes screen failures and drop-outs. We expect some dropout between screening and enrollment. Subjects who drop out prior to the successful completion of the study will be replaced. Data will be used up to the point of withdrawal. Age range: 50 years or older, inclusive; Ethnicity: all races and ethnicities.
Descripción
Inclusion Criteria:
- Stable body-weight (± 5%) for the past 3 months
- Subject is judged to be in satisfactory health based on medical history, physical examination, and laboratory screening evaluations.
- Ability to walk, sit down and stand up independently or with walking mobility aids
- Ability to lie in a supine or elevated position for up to 3 hours
- Discharged within 30 days after a hospital admittance for >48-hours (recently hospitalized group only)
- Diagnosis of heart failure (stages 2-4 heart failure based on the New York Heart Association Functional Class; heart failure group only)
- Willingness and ability to comply with the protocol
Exclusion Criteria:
- Insulin dependent diabetes mellitus
- Established diagnosis of malignancy
- History of untreated metabolic diseases including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Presence of fever within the last 3 days
- Use of short course of oral corticosteroids within 4 weeks preceding study day
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
- (Possible) pregnancy
- Already enrolled in another clinical trial and that clinical trial interferes with participating in this study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Controls
Study subjects that are eligible based on inclusion/exclusion criteria Screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Study day(s): may include combinations of stable tracer infusions and with blood draws, cognitive and muscle performance testing |
Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Age-related changes in whole-body protein and amino acid metabolism
Periodo de tiempo: 2 hours
|
Whole-body production rate measured after stable tracer administration |
2 hours
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Age-related changes in whole-body glucose metabolism
Periodo de tiempo: 2 hours
|
Whole-body production rate measured after stable tracer administration |
2 hours
|
|
Age-related changes in whole-body fat metabolism
Periodo de tiempo: 2 hours
|
Whole-body production rate measured after stable tracer administration |
2 hours
|
|
Age-related changes in depression as measured by the Hospital Anxiety and Depression Scale (HADS) and Geriatric Depression Scale (if applicable)
Periodo de tiempo: baseline visit
|
Self-reported depression measured by a validated questionnaire related to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms). A higher score indicates a worse outcome (greater self-reported depression symptoms). |
baseline visit
|
|
Age-related changes in anxiety as measured by the Hospital Anxiety and Depression Scale (HADS)
Periodo de tiempo: baseline visit
|
Anxiety measured by a validated questionnaire related to anxiety-related symptoms. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) related to anxiety. A higher score indicates a worse outcome (greater self-reported anxiety symptoms). |
baseline visit
|
|
Age-related changes in mood as measured by the Profile of Mood State (POMS)
Periodo de tiempo: baseline visit
|
A psychological distress scale to measure the mood disturbance in 6 domains - fatigue-inertia, vigor-activity, tension-anxiety, depression-dejection, anger-hostility, and confusion-bewilderment in the past week. Each item on the questionnaire is awarded a score from 0 ("not at all") to 4 ("extremely"), except "Relaxed" and "Efficient" scored 4 ("not at all") and 0 ("extremely"), based on the intensity of the assessed feeling in the past week. |
baseline visit
|
|
Age-related changes in health status
Periodo de tiempo: baseline visit
|
Health status assessed by Health-Related Quality of Life Scale (HR-QoL) |
baseline visit
|
|
Age-related changes in physical activity
Periodo de tiempo: baseline visit
|
Physical activity assessed by Physical Activity Scale for the Elderly (PASE) |
baseline visit
|
|
Age-related changes in sleep quality
Periodo de tiempo: baseline visit
|
Sleep quality assessed by Pittsburgh Sleep Quality Index |
baseline visit
|
|
Age-related changes in nutritional status
Periodo de tiempo: baseline visit
|
Nutritional status assessed by Mini-Nutritional Assessment |
baseline visit
|
|
Age-related changes in attention and executive functions as measured by Trail Making Test (TMT)
Periodo de tiempo: baseline visit
|
In Part A, the examinee is instructed to connect a set of 25 circles with numbers as quickly as possible while maintaining accuracy. In Part B, the examinee is instructed to connect a set of 25 circles, alternating between numbers and letters, as quickly as possible while maintaining accuracy. Measures attentional resources and is a measure of the frontal lobe "executive" functions of visual search, set-switching and mental flexibility. The total time in seconds was reported for each measure. |
baseline visit
|
|
Age-related changes in overall cognitive abilities as measured by Montreal Cognitive Assessment (MoCA)
Periodo de tiempo: baseline visit
|
MoCa assesses several cognitive domains and is used for the screening of mild cognitive impairment. Total scores range from 0-30 with lower scores indicating decreased functioning. |
baseline visit
|
|
Age-related changes in exercise capacity
Periodo de tiempo: baseline visit
|
Functional exercise capacity assessed by 6-minute walk test |
baseline visit
|
|
Age-related changes in physical weakness (frailty)
Periodo de tiempo: baseline visit
|
Physical weakness assessed by Short Physical Performance Battery |
baseline visit
|
|
Age-related changes in skeletal muscle strength of the upper extremity
Periodo de tiempo: baseline visit
|
Skeletal muscle strength measured by handgrip test |
baseline visit
|
|
Age-related changes in skeletal muscle strength of the lower extremity
Periodo de tiempo: baseline visit
|
Skeletal muscle strength measured by one-leg test |
baseline visit
|
|
Age-related changes in respiratory muscle strength
Periodo de tiempo: baseline visit
|
Respiratory muscle strength measured by a hand-held mouth pressure device (Micro RPM) |
baseline visit
|
|
Age-related changes in balance
Periodo de tiempo: baseline visit
|
Skeletal muscle strength measured by Berg Balance Scale and balance platform |
baseline visit
|
|
Age-related changes in gut microbiota
Periodo de tiempo: baseline visit
|
The amount and types of microbiota assessed in collected stool sample |
baseline visit
|
|
Age-related changes in gut function
Periodo de tiempo: baseline visit
|
Gut function assessed by Gastrointestinal Symptom Rating Scale, a 15-item instrument designed to assess the symptoms associated with common gastrointestinal disorders. A higher score indicates worse outcomes (more discomfort). |
baseline visit
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Age-related changes in hand dexterity
Periodo de tiempo: baseline visit
|
Hand dexterity assessed by the Nine-Hole Peg Test (9-HPT), a standardized, quantitative assessment in which the subject is asked to take pegs from a container, one by one, and place them into the holes on the board. Time upon completion will be recorded using both left and right hand, separately. |
baseline visit
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2021-1413
- 82-Aging (Otro identificador: CTRAL)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Data may be shared upon request for up to 6 years beyond completion of the trial based on methods/proposal approved by both parties' institutional review committees. Individual participant data that underlie the results of the trial may be shared after de-identification (text, tables, figures, and appendices). Additional documents available per request include: study protocol, statistical analysis plan, and informed consent. Requests should be directed to Dr. Marielle Engelen (mpkj.engelen@ctral.org).
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .